We are live on ! Find out more
LPCN icon

Lipocine
LPCN

26 hedge funds and large institutions have $13.1M invested in Lipocine in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

766% more capital invested

Capital invested by funds: $1.51M → $13.1M (+$11.6M)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

19.59% more ownership

Funds ownership: 9.77% → 29.36% (+20%)

18% more funds holding

Funds holding: 22 → 26 (+4)

Holders
26
Holders Change
+4
Holders Change %
+18.18%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DP
Diadema Partners
New Jersey
+$878K
2
IC
Ikarian Capital
Texas
+$671K
3
PAP
Persistent Asset Partners
Hong Kong
+$237K
4
BFM
Boothbay Fund Management
New York
+$185K
5
Ameriprise
Ameriprise
Minnesota
+$54.2K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$73.5K
2
Citadel Advisors
Citadel Advisors
Florida
-$40.7K
3
Barclays
Barclays
United Kingdom
-$26.8K
4
Osaic Holdings
Osaic Holdings
Arizona
-$7.23K
5
TRCT
Tower Research Capital (TRC)
New York
-$3.33K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Squadron Capital Management
Illinois
$4.26M +$1.78M +530,000 New
DP
2
Diadema Partners
New Jersey
$2.1M +$878K +260,939 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.78M – – –
IC
4
Ikarian Capital
Texas
$1.6M +$671K +199,542 New
BlackRock
5
BlackRock
New York
$717K – – –
PAP
6
Persistent Asset Partners
Hong Kong
$567K +$237K +70,576 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$502K +$4.62K +1,374 +2%
BFM
8
Boothbay Fund Management
New York
$441K +$185K +54,893 New
Renaissance Technologies
9
Renaissance Technologies
New York
$300K +$4.37K +1,300 +4%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$200K -$73.5K -21,852 -47%
State Street
11
State Street
Massachusetts
$150K – – –
Ameriprise
12
Ameriprise
Minnesota
$129K +$54.2K +16,104 New
Northern Trust
13
Northern Trust
Illinois
$106K – – –
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$97.5K – – –
Jane Street
15
Jane Street
New York
$84.9K +$35.6K +10,574 New
UBS Group
16
UBS Group
Switzerland
$45K +$12.9K +3,837 +217%
Morgan Stanley
17
Morgan Stanley
New York
$6.03K +$592 +176 +31%
CSC
18
Caldwell Sutter Capital
California
$3.78K – – –
Group One Trading
19
Group One Trading
Illinois
$1.3K – – –
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$1K +$242 +72 +7,200%
Osaic Holdings
21
Osaic Holdings
Arizona
$947 -$7.23K -2,150 -95%
HWM
22
HighMark Wealth Management
Minnesota
$803 +$336 +100 New
Fidelity Investments
23
Fidelity Investments
Massachusetts
$618 +$61 +18 +31%
SS
24
SBI Securities
Japan
$538 – – –
T
25
Tidemark
California
$474 – – –
1
2

LPCN Hedge Fund Activity: Q4 2025 in Review

26 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2025, worth a combined $13.1M — up 766% from $1.51M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new LPCN positions and 4 closed out — a net gain of 4 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Diadema Partners, opening a new position worth an estimated $878K. The largest seller was Susquehanna International Group, cutting an estimated $73.5K.

  • 26 institutional investors held Lipocine (LPCN) as of Q4 2025, up from 22 in Q3 2025.
  • Funds reported $13.1M of Lipocine stock for Q4 2025, up 766% quarter-over-quarter.
  • 8 funds opened new Lipocine positions in Q4 2025 and 4 closed out, a net change of +4 holders.
  • The largest Lipocine buyer in Q4 2025 was Diadema Partners, an estimated $878K added.
  • The largest Lipocine seller in Q4 2025 was Susquehanna International Group, an estimated $73.5K sold.

Based on aggregated 13F filings for Q4 2025.